Astral Codex Ten - The Compounding Loophole
Now that we’ve gone over the pharmacology of the GLP-1 agonists, let’s get back to the economics. Last time, we asked - how will the economy handle a $12,000/year drug that everyone wants? Now we have an answer: the compounding loophole. Compounding pharmacies are pharmacies that make some drugs on site. Don’t imagine fancy chemistry labs; imagine something more like them putting powder into capsules. They can get you unusual doses (for example, if you’re a hyper-responder and need a pill smaller than the smallest standard version) or unusual formulations (for example, if you have digestive problems and want a usually-solid medication as a liquid, or vice versa.) Compounding pharmacies aren’t supposed to compete with Big Pharma. They’re usually just some storefront where one guy with a PharmD degree pours powders into things. Big Pharma has the patents and heavily-FDA-regulated factories. It would be unfair to let compounding pharmacies ignore the patents and regulations everyone else has to follow. So they’re usually under lots of restrictions. But the law says that compounding pharmacies are allowed to step in and compete with Big Pharma during a shortage. And guess which drugs are in constant shortage because every obese person in the country has wanted them for the past year? So enterprising startups have hit upon the business model of connecting would-be patients to friendly doctors and compounding pharmacies. From the customer perspective, this looks like filling in a form on a website and getting cheap GLP-1 agonist drugs in the mail the next day. How do the compounding pharmacies get it? They say it’s through the same factories that make the official version for Big Pharma. If I understand the situation, nameless Chinese factories¹ make the chemical itself, and Novo Nordisk (the pharmaceutical company that owns the official patent) does some fancy encapsulation work at their own plants. But they have a permanent capacity problem because of logistical and regulatory issues, so the nameless Chinese factories sell the extra to the compounding pharmacies on the side. How much does is cost? HenryMeds is $297/month, Eden is $296, Mochi is $254 - compared to the $1,300/month you’d pay for the official product. This isn’t covered by insurance, so it’s still not affordable for lots of people. But it’s more affordable than the $1,300/month version. Also, there’s not a shortage of it. Why doesn’t it cost even less? This is still a mystery to me. The compounding pharmacies are circumventing the patent, so they don’t need to pay back investment. And there’s a lot of competition between various compounders and telemedicine startups - even 23andMe is getting in on the deal now! And some Harvard doctors recently published a paper saying that the unit cost to the manufacturer is only about $5/month. Maybe the bottleneck is FDA-approved factories, or high-capacity compounding pharmacies. Or maybe Harvard doctors with no skin in the game are assuming too many things away, and $250 is the best we’ll get for now. Is the compounded version as safe as the regular version? The chemicals coming from the same factories is a good start, but might there be problems with the last few steps done at the pharmacy? The usual suspects have written countless articles warning that compounded semaglutide might not be safe; the really ambitious ones have mentioned that adverse events have even been reported to the FDA. But this article gives away the game:
This doesn’t mean that the FDA-approved version is 100x more dangerous than the compounded version - you’d need to know how many prescriptions were filled, and whether one type of patient is more likely to report than the other. It just means you can ignore all the people saying “How can you trust compounding pharmacies when there are ADVERSE EVENTS associated with them?!?!” The other safety concern is the salt form. FDA-approved semaglutide is the free base² (ie the semaglutide molecule not attached to anything). Some suppliers sell the salt version (ie semaglutide attached to an ion like sodium). The FDA has issued warnings saying that the salt version isn’t approved, that any supplier caught using the salt will be shut down, and that you should avoid compounding pharmacies because you can never be sure they’re not offering the dreaded salt form. The commentary I’ve read from chemists is that none of this matters because the salt form dissolves into the free base as soon as it’s in water (which it always is before you inject it), although other people point out that maybe there could still be some theoretical concerns about shelf life and stability. Still, the FDA is legally allowed to shut down anyone offering the salt, and all the compounding pharmacies have switched to the free base. I’m less convinced by any of this than I am by the existence of several big online communities of compounded GLP-1 drug users (eg r/compoundedsemaglutide) who overall seem pretty happy and don’t report any unusual side effects. So this is good, right? I’m pretty encouraged by it. Not only does it provide GLP-1 drugs for a quarter of the price, but also people were really worried that diabetics wouldn’t be able to get their diabetes drugs because dieters would grab them off the shelf first. But now there’s more than enough GLP-1 agonists for everybody. This dramatically demonstrates how drug shortages are mostly regulatory problems (Adderall users, take note!) What about paying back the patent-holders? That is the one disadvantage. The good news for them is that insurances mostly don’t cover these compounding pharmacies. So the people who really medically need the drugs will get them via insurance, and insurance will pay full price to the patent-holders. The compounding pharmacies will just pick off the people who only want them for cosmetic reasons, or who have bad insurance - most of whom wouldn’t have been able to get them through the normal system anyway. Don’t get me wrong, this does probably take a big chunk out of Novo Nordisk’s profits. But Novo Nordisk’s stock price currently looks like this: …and they’re now the most valuable company in Europe. So they can probably eat the loss. What happens when the shortage ends? Compounding pharmacies are only allowed to do this because of a law that suspends some drug regulations during a “shortage”, ie when the drug is on the FDA’s drug shortage list. At some point, Novo Nordisk will build enough factories to meet capacity and there won’t be a shortage anymore. What then? Will the fun be over? Will GLP-1 agonists go back to costing $1,200/month again? Will most of the current users have to stop the drug and regain the lost weight? This would make tens of thousands of people really mad. I don’t know if the FDA has the guts to offend that many people. Their style is more to crush drugs before they ever come out, before anyone knows what they’re missing. During COVID, the DEA said that telemedicine was allowed to be cheap and convenient so patients could get care during lockdown. After the pandemic died down, they tried making it hard and expensive again, but so many patients protested that they backed off. The uproar we’ll get if the FDA tries to make GLP-1 drugs expensive again will make that one look like a tempest in a teapot. But Big Pharma will be even angrier if they don’t. And besides, they can’t keep the drug on their shortage list if everyone knows there’s no shortage. I really don’t know what will happen, and I don’t envy whichever FDA official is in charge of setting a policy on this. I did see one proposed solution somewhere or other (sorry if it’s yours and I’m not crediting you). Compound pharmacies are always allowed to make compounded medications for specific patients who have a “medically necessity” for a non-FDA-approved product. So in theory, you could try something like:
This is obviously cheating. But if the FDA were desperate enough, it might let them get away with it. 1 The linked Reddit answer names a factory in Switzerland, but some other sources give a longer list of factories, most of which were in China. 2 Did you know: the slang term “based” originally comes from the free base form of a drug (as opposed to the salt). I am not making this up. You're currently a free subscriber to Astral Codex Ten. For the full experience, upgrade your subscription. |
Older messages
Lukianoff And Defining Cancel Culture
Wednesday, August 21, 2024
... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Your Book Review: Silver Age Marvel Comics
Tuesday, August 20, 2024
Finalist #9 in the Book Review Contest ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Finish signing in to Astral Codex Ten
Tuesday, August 20, 2024
Here's a link to sign in to Astral Codex Ten. This link can only be used once and expires in one hour. If expired, please try signing in again here. Sign in now © 2024 Scott Alexander 548 Market
Open Thread 343
Tuesday, August 20, 2024
... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Why Does Ozempic Cure All Diseases?
Tuesday, August 13, 2024
... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You Might Also Like
📺 ‘Agatha All Along’ More Than Pays Off
Thursday, September 19, 2024
Plus: NASA's Artemis I mission brought back some very practical — and promising — information about protecting astronauts from radiation. Inverse Daily The 'WandaVision' spinoff takes cues
Deadly reminder that phones are ultimate tracking device
Thursday, September 19, 2024
+ what Fed rate cut means for the economy
Harris' Turn To The Dark (Money) Side
Thursday, September 19, 2024
Despite a history of decrying dark money, Harris is now reaping the rewards of big, secret political donations. Kamala Harris once vowed to end dark money in politics. But now that she's benefiting
Fed Cuts Rates, Harvest Moon Photos, and a Rat Summit
Thursday, September 19, 2024
The Federal Reserve cut interest rate by a half-percentage point on Wednesday, signaling more cuts to come as it winds down efforts to combat inflation. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
What Instagram's new Teen Accounts are really about
Thursday, September 19, 2024
Plus: What we know about exploding pagers in Syria and Lebanon, the Neom controversy, and more. Sept. 19, 2024 View in browser Ellen Ioanes covers global and general assignment news as the world and
The stark reality of mass deportation
Thursday, September 19, 2024
Former President Donald Trump has promised that he will start mass deportations if he wins in November. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Fed Rate Cut, Dali Suit, and Cutting Board Bacteria
Thursday, September 19, 2024
Facts, without motives.
Numlock News: September 19, 2024 • Polar Bears, Lionel Messi, Health Inspectors
Thursday, September 19, 2024
By Walt Hickey ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
☕️ Deep cut
Thursday, September 19, 2024
The Fed went bold on interest rates... September 19, 2024 View Online | Sign Up | Shop Morning Brew PRESENTED BY EnergyX Good morning. The battle for toy supremacy has reached levels Pixar could never
IBM quietly axing thousands of jobs, source says [Thu Sep 19 2024]
Thursday, September 19, 2024
Hi The Register Subscriber | Log in The Register {* Daily Headlines *} 19 September 2024 ibm IBM quietly axing thousands of jobs, source says We did warn you, Big Blue tells The Reg, as Cisco also cuts